Tailored Exercise Training Study Among Adults With HFpEF
NCT07223242 on ClinicalTrials.gov · last registry update 2025-10-31
An unusually large phase 2/phase 3: 120 participants, more than double the 60 typical for the stage. Due to report 30 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Peak Exercise Oxygen Uptake (VO2peak). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for heart failure — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- RECRUITING
- Phase
- P2/P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- University of Texas Southwestern Medical Center
- Sponsor type
- Other
- Enrollment
- 120
- Started
- 2025-02-18
- Primary completion
- 2026-12-30 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Peak Exercise Oxygen Uptake (VO2peak)
Conditions studied
HFpEF - Heart Failure With Preserved Ejection Fraction · Diabetic Cardiomyopathies
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.